NCT01226732View on ClinicalTrials.gov

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

June 30, 2014

Conditions
Metastatic or Unresectable Solid Tumor Malignancy
Interventions
DRUG

Capecitabine

Taken orally twice daily on Days 1 through 14 of 21 day cycle.

DRUG

Hsp90 Inhibitor AUY 922

IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle

Trial Locations (3)

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, Nashville

71304

Oklahoma University, Oklahoma City

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER